These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 14438696)

  • 1. The active center of plasmin.
    RONWIN E
    Biochim Biophys Acta; 1960 Feb; 38():258-65. PubMed ID: 14438696
    [No Abstract]   [Full Text] [Related]  

  • 2. The active center of human plasmin.
    RONWIN E
    Can J Biochem Physiol; 1962 Jan; 40():57-64. PubMed ID: 14493698
    [No Abstract]   [Full Text] [Related]  

  • 3. Some aspects of the chemistry of plasmin and its inhibitors.
    NORMAN PS
    Am J Cardiol; 1960 Aug; 6():390-8. PubMed ID: 14427622
    [No Abstract]   [Full Text] [Related]  

  • 4. Properties of human plasmin.
    RONWIN E
    Can J Biochem Physiol; 1962 Jan; 40():49-55. PubMed ID: 14493697
    [No Abstract]   [Full Text] [Related]  

  • 5. Purification of components of the plasmin system.
    KLINE DL; FISHMAN JB
    Am J Cardiol; 1960 Aug; 6():387-9. PubMed ID: 14409880
    [No Abstract]   [Full Text] [Related]  

  • 6. The quantitative and clinical determination of human plasmin by the TAC method.
    RONWIN E
    Acta Haematol; 1961; 26():21-8. PubMed ID: 14493699
    [No Abstract]   [Full Text] [Related]  

  • 7. A study of plasmin in eye disease.
    UEMURA M; UEMURA Y; AKIYA S
    Am J Ophthalmol; 1962 Jul; 54():67-75. PubMed ID: 13923524
    [No Abstract]   [Full Text] [Related]  

  • 8. The differentiation of the chloroform, peptone and antigen-antibody inducible esterase activities of human serum from plasmin.
    AUSTEN KF
    Immunology; 1960 Apr; 3(2):152-73. PubMed ID: 13795183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immobilization of bioactive plasmin reduces the thrombogenicity of metal surfaces.
    Wise SG; Michael PL; Waterhouse A; Santos M; Filipe E; Hung J; Kondyurin A; Bilek MM; Ng MK
    Colloids Surf B Biointerfaces; 2015 Dec; 136():944-54. PubMed ID: 26551872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The products of degradation of human fibrinogen by plasmin. I. Separation and physicochemical properties].
    NUSSENZWEIG V; SELIGMANN M; PELMONT J; GRABAR P
    Ann Inst Pasteur (Paris); 1961 Mar; 100():377-89. PubMed ID: 13729934
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of active center and lysine binding sites of plasmin in plasmin-induced platelet activation and disaggregation.
    Lu H; Soria C; Li H; Soria J; Lijnen HR; Perrot JY; Caen JP
    Thromb Haemost; 1991 Jan; 65(1):67-72. PubMed ID: 1827215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibitors of the serine protease plasmin: probing the S3 and S3' subsites using a combinatorial library.
    Xue F; Seto CT
    J Med Chem; 2005 Nov; 48(22):6908-17. PubMed ID: 16250649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of the K4 and K5 plasmin heavy chain kringles in the fibrin clot structure destruction].
    Andrianov SI; Makogonenko EM; Kudinov SA
    Ukr Biokhim Zh (1978); 1992; 64(2):31-8. PubMed ID: 1413115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic studies on the plasminogen activation by the staphylokinase-plasmin complex.
    Shibata H; Nagaoka M; Sakai M; Sawada H; Watanabe T; Yokokura T
    J Biochem; 1994 Apr; 115(4):738-42. PubMed ID: 8089091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of streptokinase on the interaction of alpha-2-antiplasmin with different sites of plasmin molecule].
    Iusova EI; Grinenko TV; Volkov GL
    Ukr Biokhim Zh (1999); 2004; 76(2):98-106. PubMed ID: 15915719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin.
    Hunt JA; Petteway SR; Scuderi P; Novokhatny V
    Thromb Haemost; 2008 Sep; 100(3):413-9. PubMed ID: 18766256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel type of plasmin inhibitors: providing insight into P4 moiety and alternative scaffold to pyrrolopyrimidine.
    Teno N; Gohda K; Wanaka K; Tsuda Y; Akagawa M; Akiduki E; Araki M; Masuda A; Otsubo T; Yamashita Y
    Bioorg Med Chem; 2015 Jul; 23(13):3696-704. PubMed ID: 25921265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmin alters the activity and quaternary structure of human plasma carboxypeptidase N.
    Quagraine MO; Tan F; Tamei H; Erdös EG; Skidgel RA
    Biochem J; 2005 May; 388(Pt 1):81-91. PubMed ID: 15617514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human tissue kallikreins 3 and 5 can act as plasminogen activator releasing active plasmin.
    de Souza LR; M Melo P; Paschoalin T; Carmona AK; Kondo M; Hirata IY; Blaber M; Tersariol I; Takatsuka J; Juliano MA; Juliano L; Gomes RA; Puzer L
    Biochem Biophys Res Commun; 2013 Apr; 433(3):333-7. PubMed ID: 23500465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breaching the conformational integrity of the catalytic triad of the serine protease plasmin: localized disruption of a side chain of His-603 strongly inhibits the amidolytic activity of human plasmin.
    Mhashilkar AM; Viswanatha T; Chibber BA; Castellino FJ
    Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5374-7. PubMed ID: 8506386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.